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Abstract 
Background: Chronic pain (CP) is a common cause of human suffering. The transition of pain 
symptoms to CP is therefore important to act on. The dysfunctional hypothalamic-pituitary-adrenal 
(HPA) axis, presented as hypocortisolism or hypercortisolism, is considered as an important factor in 
the onset of CP. However, the precise mechanism behind the dysfunctional HPA axis remains unclear. 
Objective: A systematic review and meta-analysis were conducted to investigate the causal relationship 
between a dysfunctional HPA axis and the onset of CP. The purpose of the study was to quantify 
whether a dysfunctional HPA axis is a risk factor in the onset of CP, to determine whether the 
dysfunctional HPA axis presented as hypocortisolism specifically, and to examine moderators of the 
relationship between a dysfunctional HPA axis and the onset of CP. Methods: The literature search 
focused on prospective cohort studies investigating the dysfunctional HPA axis, presented as low or 
high cortisol levels, in the onset of CP in adults. The review reported the characteristics, results and 
main findings of the selected studies. The meta-analysis explored the overall effect size of the causal 
relationship and the influence of hypocortisolism. Furthermore, the moderators gender, age and 
traumatic life events were examined. Results: The literature search identified five studies meeting the 
inclusion criteria, three of which used analytic methods allowing for meta-analysis. In the studies new-
onset CP was either determined as musculoskeletal pain or as chronic widespread pain. The systematic 
review presents some support that young adults showed hypocortisolism and psychologically-at-risk 
middle-aged adults showed hypercortisolism, both leading to a higher risk of new-onset CP. 
Furthermore, the likelihood of the onset of CP was larger for females, older individuals and traumatized 
individuals. The meta-analysis shows a non-significant slightly increased risk of CP by a dysfunctional 
HPA axis (odds ratio = 1.15, 95% confidence interval = 0.83, 1.59). Conclusions: The small number 
of available studies, which also reveal inconclusive findings, cannot confirm a dysfunctional HPA axis 
as risk factor of new-onset CP. The current review suggests that severe stress in individuals influences 
the transition from pain to CP and subsequently leads to HPA axis dysfunction. However, more robust 
longitudinal studies are needed to clarify this relationship. In particular, risk groups with vulnerabilities 
to stress should be studied to confirm stress as a moderator. 
Key Words: chronic pain, hypothalamic-pituitary-adrenal axis, stress, systematic review, meta-
analysis. 
 
1. Introduction 
Pain has an important function in the body’s response system and plays a key role in signaling 
danger. Pain acts by activating threat responses, through which the problem is either mitigated or the 
pain is no longer experienced. Pain also acts as a negative reinforcer and suppresses behavior that leads 
to pain. In case of acute pain, avoiding stimuli that provoke pain is an adaptive response to prevent 
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further damage. However, in the case of chronic pain (CP), the intended protective response to prevent 
further danger, such as the experienced pain, is no longer effective (Eccleston, 2013).  
CP is defined as an agonizing pain which persists either continually or intermittently for at least 
three to six months (Lumley et al., 2011; Machikanti, Singh, Datta, Cohen, & Hirsch, 2009). CP is used 
as an umbrella term for several pain conditions of which the most familiar are low back pain, 
musculoskeletal pain, fibromyalgia, widespread pain, headache and phantom limb pain (Cieza et al., 
2004; Melzack & Katz, 2013; Woda, Picard, & Dutheil, 2016).  
In today’s society, CP is a common cause of human suffering (Muthunarayanan, Ramraj, & Russel, 
2015) with an adult population prevalence of 27% in Europe and 30% in the United States (Johannes, 
Le, Zhou, Johnston, & Dworkin, 2010; Leadley, Armstrong, Lee, Allen, & Kleijnen, 2012). CP reduces 
quality of life considerably through high psychological burden, occupation inabilities and disturbed 
relationships (Gard et al., 2012; Verhaak, Kerssens, Dekker, Sorbi, & Bensing, 1998; Yamada, 
Matsudaira, Imano, Kitamura, & Iso, 2016). 
CP is often viewed from a dualistic perspective, either caused by biological or psychosocial factors, 
although current pain models recognize the integration of these processes (Lumley et al., 2011). To 
illustrate, CP acts as a chronic stressor which could change pain thresholds and could exacerbate pain 
(hyperalgesia) (McEwen & Kalia, 2010). Exacerbating pain is often accompanied with negative beliefs 
and hypervigilance to pain, which can subsequently lead to pain anxiety (Eccleston, 2013). A plausible 
theory that further explains the transition from acute pain to CP is the addition of behavioral patterns, 
obstructing the control mechanisms for an adequate pain response. As a result, non-threatening stressors 
evoke fear-avoiding behavior towards the painless stimuli. The fear-avoiding reactions lead to 
disabilities and distress (Davey, 2016). When the pain is accompanied with stress and increased pain 
sensitivity, pain symptoms can gradually change into CP (Eccleston, 2013). 
CP can disrupt bodily functions controlled by the brain, such as the homeostatic regulation system, 
by evoking a physiological stress response, in an attempt to reestablish homeostasis (Melzack & Katz, 
2013). One of the major stress systems in the brain is the hypothalamic-pituitary-adrenal (HPA) axis, 
which reacts to both physical and psychological stressors (Colloca & Benedetti, 2007; Hannibal & 
Bishop, 2014; McEwen, 1998, 2007; Tak & Rosmalen, 2010). While there are other neurobiological 
determinants in CP, such as changes in grey and white matter (Kregel et al., 2015), dysregulation of the 
hypothalamus (Qiu et al., 2013) and the anterior cingulate cortex (Ringel & Drossman, 1999), the 
dysfunctional HPA axis is the most investigated neurobiological factor associated with CP (Tak & 
Rosmalen, 2010).  
The HPA axis initiates a neurobiological process which is set in motion when an individual 
encounter a stressor (Figure 1). The stressor leads to the secretion of corticotrophin-releasing hormone 
(CRH) and arginine vasopressin hormone (AVP) from the paraventricular nucleus of the hypothalamus 
(Chrousos & Gold, 1992). The interaction of the CRH and AVP hormones subsequently produces a 
reaction in the anterior pituitary gland which releases the adrenocorticotropic hormone (ACTH). ACTH 
  
6 
subsequently stimulates glucocorticoids (GC) secretion, primarily cortisol, from the adrenal gland 
(McEwen & Kalia, 2010). When the hormones reach a certain level, the GC regulates the release of 
further ACTH and CRH via a negative feedback system. This means that released cortisol inhibits the 
hypothalamus and anterior pituitary gland, lowering further cortisol production (Keller-Wood & 
Dallman, 1984).   
 
Figure 1. Schematic representation of the HPA axis. The hypothalamus secretes CRH that acts on the 
pituitary gland. In response, the pituitary gland releases ACTH and activates the adrenal glands to 
release cortisol which produces metabolic effects. Cortisol responds to the hypothalamus and pituitary 
gland through negative feedback. HPA = hypothalamic-pituitary-adrenal; CRH = corticotropic-
releasing-hormone; ACTH = adrenocorticotropic hormone. Reprinted from “The endocrine system: 
An overview,” by S. Hiller-Sturmhöfel and A. Bartke, 1998, Alcohol Health & Research World, 
22(4), p. 162. Copyright 2012, permission was not required.  
 
Cortisol is a corticosteroid ‘stress’ hormone and plays a key role in the HPA axis functioning 
(McEwen, 1998). The basal functions of cortisol include maintaining day-to-day blood glucose levels 
and suppressing non-vital organ systems to provide energy for the brain and neuromuscular system 
(Heim, Ehlert, & Hellhammer, 2000). The production of cortisol provides important bodily functions 
that confer either a protective or damaging role (McEwen, 1998). Protective functions of cortisol 
include regulation of intermediary metabolism, cardiovascular function, growth and the immune system 
(McEwen & Kalia, 2010).  
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In case of acute stress, the HPA axis responds by secreting a higher level of cortisol, which is 
beneficial for cognitive functions, such as adaptation, memory and learning (McEwen, 1998; McEwen 
& Gianaros, 2011). Prolonged stress, however, can disrupt the HPA axis, leading to the overproduction 
of cortisol, called ‘hypercortisolism’. Over time, prolonged stress can lead to an exhausted stress 
response with alterations in the HPA axis that causes reduced cortisol production, called 
‘hypocortisolism’ (Guilliams & Edwards, 2010). A lack of cortisol may result in increased vulnerability 
to bodily disorders, autoimmune disorders, inflammation and CP (Heim et al., 2000; McEwen, 1998). 
Hypocortisolism will increase sensitivity to stress but is also considered a consequence of previous 
stressful experiences, and it is associated with the onset of CP (Fries, Hesse, Hellhammer, & 
Hellhammer, 2005; Heim et al., 2000; McEwen & Gianaros, 2011). Hypocortisolism is found in 20-
25% of patients with chronic pelvic pain, fibromyalgia and low back pain (Griep, Boersma, Lentjes, & 
Prins, 1998; Gur, Cevik, Nas, Colpan, & Sarac, 2004; Heim, Ehlert, Hanker, & Hellhammer, 1998; 
Heim et al., 2000).  
Furthermore, the influence of the dysfunctional HPA axis on the onset of CP seems to be affected 
by a number of moderators, such as age and gender. Individuals aged 50 year and older have a two-fold 
increased chance to develop CP (Gatchel, Peng, Peters, Fuchs, & Turk, 2007) resulting in a total of 61% 
of older individuals that have reported CP in large US community-based samples (Watkins, Wollan, 
Melton 3rd, & Yawn, 2007). In addition, age affects the overall functioning of the HPA axis. Research 
shows that a prolonged cortisol response to stress in individuals above 65 years is due to a delayed 
inhibition of ACTH secretion, in comparison to young individuals. This results in slower recovery after 
stress and longer continuation of a stressor, such as pain (Veldhuis, Sharma, & Roelfsema, 2013; 
Wilkinson, Peskind, & Raskind, 1997; Wilkinson et al., 2001).  
Prevalence rates, with respect to gender, show that CP is more common among females, with a 
prevalence of 5% to 41% in females and 4% to 29% in males (Gureje, Von Korff, Simon, & Gater, 
1998; Hardt, Jacobsen, Goldberg, Nickel, & Buchwald, 2008). In addition, females that develop CP 
also seem to have higher stress levels (McBeth & Jones, 2007). 
The occurrence of traumatic life experiences is a third moderator of the dysfunctional HPA axis 
and subsequent CP. It is thought that psychological stress can change into physical symptoms and 
illness, accompanied by HPA axis dysfunction (McEwen & Kalia, 2010). To illustrate, growing 
evidence shows that traumatic life events, such as divorce, sexual or physical abuse and conflicts with 
relatives or friends, can predispose individuals to develop CP, such as pelvic pain and fibromyalgia 
(Imbierowicz & Egle, 2003; Meltzer-Brody, Leserman, Zolnoun, Steege, & Teich, 2007). Furthermore, 
traumatized individuals with a persistent lack of cortisol are more vulnerable to the development of CP 
(Heim et al., 2000; McEwen & Gianaros, 2011).  
An explanation for the relation between psychological stress and pain can be that psychological 
stress, such as traumatic life events, influences neurobiological pathways, pathways which may be 
similar or comparable to neurobiology seen in CP (Lind, Delmar, & Nielsen, 2014). For instance, a 
  
8 
dysfunctional HPA axis is found in 28% of fibromyalgia patients with childhood trauma (Weissbecker, 
Floyd, Dedert, Salmon, & Sephton, 2006).  
The beforementioned findings indicate that a dysfunctional HPA axis is associated with CP. The 
moderators age, gender and traumatic life events seem to contribute to the dysregulation of the HPA 
axis. However, many of the existing studies examined the dysfunctional HPA axis in CP patients in 
clinical settings and these studies were not longitudinal in nature.  
The precise mechanism of the HPA axis as contributing factor in CP is still unclear. The question 
remains whether alterations in HPA axis are the result of abnormal pain perception or that CP can be 
seen as a consequence of HPA axis dysfunction (Adler & Geenen, 2005) The transition from no (or 
little) pain to CP is an important phase to act on. It remains to be elucidated whether a dysfunctional 
HPA axis precedes the onset of CP in relatively healthy people. The current study investigates previous 
longitudinal studies on the causal relation between a dysfunctional HPA axis and the onset of CP 
through a systematic review and a meta-analysis. Findings that establish a dysfunctional HPA axis prior 
to CP can provide directions for effective pharmacotherapy and/or stress-reducing interventions. 
Ultimately, this can prevent the shift to CP. 
The primary purpose of the current study is to quantify whether a dysfunctional HPA axis is 
considered an important risk factor in the onset of CP. Cohort studies that examined the cortisol levels 
of participants prior to the onset of CP will be investigated to determine the overall effect size. Since 
other factors may influence the dysfunctional HPA axis leading to the onset of CP, three moderators 
are also explored, including a) age; b) gender and; c) traumatic life events. Insight in the effect of these 
moderators can be useful in the early detection of CP symptoms, creating possibilities to customize 
treatments. 
It is hypothesized that the participants from the selected cohort studies show a dysfunctional HPA 
axis, either presented as hypocortisolism or hypercortisolism, as risk factor prior to the onset of CP. 
Since specifically hypocortisolism is associated with the onset of CP, a subsequent goal is to identify 
whether the dysfunctional HPA axis is presented as hypocortisolism. It is further hypothesized that, a) 
a higher number of females shows hypocortisolism in comparison to males; b) a higher rate of 
hypocortisolism is found in older aged individuals in comparison to young individuals and; c) a 
traumatic life event increases the chances of a dysfunctional HPA axis, leading to the onset of CP. 
 
2. Methods and Materials 
The present study is part of a larger systematic review focusing on risk factors of Medical 
Unexplained Physical Symptoms (MUPS). The current study focuses specifically on the dysfunctional 
HPA axis as a neurobiological risk factor of CP. 
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2.1. Selection and eligibility 
This systematic review and meta-analysis were performed according to the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA; Moher et al, 2015) guidelines to formulate 
the pre-specified eligibility criteria using specific study characteristics, such as study design, 
population, type of risk factor and outcome.  
Eligible for inclusion were longitudinal cohort studies (prospective, retrospective and case-control) 
with baseline measurements of cortisol levels and follow-up(s) of the onset of CP in adults. Studies 
with participants of 18 years and older with a minimal sample size of N > 10 are included. The search 
was limited to journal articles published in Dutch and English and publications from or after 1997. 
Cross-sectional and intervention studies were excluded. 
 
2.2. Literature search 
A comprehensive search was conducted for the larger ongoing research study investigating the risk 
factors of MUPS. Articles were retrieved from electronic databases, EBSCOhost, EMBASE, 
PsychINFO, Pubmed and Web of Science. The search terms indicative of 1) risk factors (e.g., 
psychological, neurobiological and social); 2) cohort studies, and; 3) MUPS-disorders (e.g., 
fibromyalgia, low back pain, headache) were combined (Appendix A). For the current study, the cohort 
studies that investigate cortisol as a risk factor for CP were selected. The titles and abstracts were 
screened using the eligibility and exclusion criteria. Possible eligible articles for data extraction were 
identified after full-text review. The electronic search was supplemented by a manual review of 
reference lists of the included articles to find other potentially important articles. These stages of 
screening were independently performed by three reviewers (W.K., M.T. and C.S.). Disagreements 
were resolved by consensus. One reviewer (W.K.) examined the final included articles to confirm all 
inclusion criteria were met. 
 
2.3. Data extraction 
Information was extracted from the selected articles by adopting and customizing the data 
extraction template for systematic reviews from The Cochrane Collaboration (Higgins & Green, 2011) 
to tabulate findings of included articles. The extracted information contains: the name of first author, 
year of publication, study design, population, sample size, risk factor measurements (cortisol levels in 
either serum, saliva or urine), outcome (type of CP), statistical methods, and results. The potential 
moderators, gender, age and reported traumatic life events, were taken into account if possible. The 
current study addressed a qualitative approach by summarizing the findings and using the corresponding 
descriptive statistics of the included studies. Furthermore, a quantitative approach resulted in statistical 
analyses of included studies with comparable statistical methods.  
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2.4. Quality assessment 
The risk of bias was systematically assessed using a modified Newcastle-Ottawa Scale (NOS) for 
evaluating the quality of the cohort studies (Wells et al., 2010). The NOS consists of eight items with 
three subscales to score the quality of included studies: 1) selection; 2) comparability and; 3) outcome. 
The quality of the studies was rated by awarding stars in each domain that resulted in a “good”, “fair” 
or “poor” quality score for each study (Appendix B). The total maximum score of these three subsets is 
9. A study which scored ³ 6 was considered a high-quality study as required within the standard criterion 
of NOS.  
 
2.5. Levels of evidence 
The level of evidence was determined using four levels, when the individual quality of the studies 
was assessed. “Strong” was indicative of consistent findings (³ 75%) in at least two good quality studies 
or one good-quality study and at least three fair studies, “moderate” was indicative of consistent findings 
(³ 75%) in one good-quality study and at least one poor-quality study or at least three fair-quality 
studies, “weak” was indicative of findings of two fair studies or consistent findings (³ 75%) in at least 
three or more poor-quality studies, and “inconclusive” was indicative of inconsistent findings 
irrespective of study quality or less than three poor-quality studies available. 
 
2.6. Statistical analyses (meta-analysis) 
Data was analyzed using Comprehensive Meta-Analysis (CMA) software, version 3.3.070. For the 
first hypothesis, the random-effects pooling method was used, with the Odds Ratio (OR) of each study 
outcome with the DerSimonian-Laird and resulted in the estimated mean of the distribution of effects. 
The 95% confidence intervals (CI) for each outcome were calculated around I2. The I2 statistic reflects 
the proportion of the total variance explained by the heterogeneity in the predictive value of cortisol 
level in the onset of CP.  
For the second hypothesis subgroup analyses and meta-regression were conducted to examine 
potential signs of heterogeneity. The predefined subgroup analyses included: a) gender; b) age and; c) 
traumatic life events. The Q test was used to examine heterogeneity, where a significant Q test shows 
between-subgroups variation, indicating the presence of moderator effects. 
 
3. Results 
3.1. Overview of search 
Figure 2 summarizes the selection of articles for the systematic review and meta-analysis. The 
literature search identified 13.135 articles, and these were imported into EndNote X7 (Clarivate 
Analytics, PA, USA). There were no additional articles identified from manual search for further 
screening. After removing duplicate articles, 7707 remained for title and abstract screening for the full 
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research study. Five articles remained for full-text review and were closely examined. All of them 
fulfilled the inclusion criteria. Remaining articles were not assessed for full-text for the main reasons 
that the examined risk factors and outcomes were different from the risk factor and outcome, 
dysfunctional HPA axis and CP, respectively. From each article data was extracted, and the results were 
summarized. Suitable summary statistics for conducting the meta-analysis were available from three of 
the five articles. The remaining two articles used statistical methods that do not produce effect estimates 
that can be converted to ORs.  
The number of included studies for the meta-analysis is not sufficient to conduct all the 
hypothesized moderation and regression analyses which will lead to insufficient power. Also, the 
available data required for those analyses was limited in most of the studies. Therefore, the meta-
analysis serves as complementary to the systematic review.  
 
Figure 2. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) study flow 
diagram. 
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3.2. Methodological quality 
Table 1 presents the quality scores for the studies, assessing risk of bias. Four studies were 
considered good quality (Generaal et al., 2016; McBeth et al., 2007; Schell, Theorell, Hasson, Arnetz, 
& Saraste, 2008; Tak, Bakker, & Rosmalen, 2009), and one was rated as fair quality (Paananen et al., 
2015). The risk of bias in some studies limited the causal inference. The main reasons being  
measurement of outcome (e.g., self-reports) and exposure (low observational quality) (Paananen et al., 
2015), lack of heterogeneous populations (e.g., young adults and adults from one working environment 
(Paananen et al., 2015; Schell et al., 2008), absence of adjustment for a key potential confounder 
(marital status) in all five studies, and lack of adequate participation at follow-up in one study (Tak et 
al., 2009). In general, the five studies together represented high methodological quality with the mean 
value 6.2.   
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Table 1 
Adapted risk of bias assessment (Newcastle-Ottawa Quality Assessment Scale Criteria). 
  Selection   Comparability  Outcome   
 
 
Study 
 
Representativeness of 
cohort 
 
Selection of cohort 
 
Ascertainment of 
exposure 
 
Outcome of 
interest was not 
present at start 
of study 
 
Comparability of cohorts 
or analyses controlled for 
confounders 
 
Assessment of 
outcome 
Follow-up long 
enough for 
outcome to 
occur (Median 
duration of 
follow-up 24 
months) 
 
Adequacy of  
follow-up 
 
Quality score 
Generaal et al. 
(2016) 
The cohort is 
representative of the 
large sample size and 
the selected subjects 
are similar ★ 
Participants were 
recruited from the 
Netherlands Study 
of Depression and 
Anxiety and free 
from chronic pain at 
baseline ★ 
Saliva cortisol ★ Yes ★ Sociodemographic 
variables, cortisol 
sampling factors, 
laboratory site and 
respiration rate; body 
mass index, smoking, 
alcohol intake, physical 
activity, chronic somatic 
diseases, use of anti-
inflammatory 
medication, b-blocking 
agents and other heart 
medication and; lifetime 
depression and/or anxiety 
and use of anti-
depressants were 
adjusted for proportional 
hazard models ★ 
Self-report with 
Chronic Pain 
Grade 
questionnaire 
Yes ★ 72% participated at 
the two, four, and 
six-year follow-up ★ 
Good 
McBeth et al. 
(2007) 
The cohort is 
representative of the 
community. 
Participants had similar 
cortisol levels at 
baseline in comparison 
with the general 
population ★ 
Healthy participants 
were recruited from 
the population 
registers from three 
primary care 
physicians in the 
UK and were 
psychologically at-
risk of future 
chronic pain ★ 
Saliva cortisol ★ Yes ★ Age, gender and 
psychosocial factors 
(general health, 
depression and anxiety, 
life events and sleep 
problems) were adjusted 
for odds ratio models ★ 
Self-report with 
sections of the 
Somatic 
Symptom 
Checklist and 
the Illness 
Behavior 
Subscale of the 
Illness Attitude 
Scale 
Yes ★ 93% participated 
at the 15-month 
follow-up ★ 
 
Good 
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Table 1 (continued) 
  Selection   Comparability  Outcome   
 
 
Study 
 
Representativeness of 
cohort 
 
Selection of cohort 
 
Ascertainment of 
exposure 
 
Outcome of 
interest was not 
present at start 
of study 
 
Comparability of cohorts 
or analyses controlled for 
confounders 
 
Assessment of 
outcome 
Follow-up long 
enough for 
outcome to 
occur (Median 
duration of 
follow-up is 24 
months) 
 
Adequacy of 
follow-up 
 
Quality score 
 
Paananen et al. 
(2015) 
The cohort is 
socioeconomically 
representative with a 
large sample size ★ 
Participants were 
recruited from the 
Western Australian 
Pregnancy Cohort 
(Raine) Study. The 
current cohort only 
concerns young 
adults 
Serum cortisol during 
the Trier Social 
Stress Test 
Yes ★ Oral contraceptive use, 
smoking, body mass index, 
physical activity level and 
depressive symptoms were 
adjusted for odds ratio 
models ★ 
Self-report with 
five questions 
of the Örebro 
Musculoskeletal 
Pain 
Questionnaire 
Yes ★ 54-61% of females 
and 45-49% of 
males participated 
in the 4-year 
follow-up 
respectively ★ 
Fair 
Schell et al. 
(2008) 
The cohort is not 
representative of the 
(working) community 
with a small, 
homogenous sample 
drawn from an 
occupation-specific 
working environment 
Participants are 
healthy media 
workers and were 
recruited from three 
news departments at 
the Swedish 
Broadcasting 
Companies of 
which one in a 
medium-sized town 
and the other two in 
the national capital 
★ 
Saliva cortisol ★ Yes ★ Age and gender were 
adjusted for multilevel 
linear regression models ★ 
Self-report of 
total sum of 
pain with the 
visual analogue 
scale 
Yes ★ 84% participated at 
the 12-month 
follow-up ★ 
Good 
Tak et al. 
(2009) 
The cohort is truly 
representative of the 
community with a 
large sample size. 
Participants covered 
low, middle and high 
socio-demographic 
profiles and were 
drawn from several 
residential areas in 
Groningen ★ 
Participants were 
recruited from the 
Prevention of Renal 
and Vascular End 
stage Disease 
(PREVEND) study 
with a wide age 
range ★ 
24-h UFC ★ 
 
 
Yes ★ Age, gender, depression, 
body mass index, smoking, 
alcohol use, frequency of 
exercise and urinary 
volume were adjusted for 
odds ratio models ★ 
Participants 
completed the 
somatization 
section of the 
computerized 
assessment of 
the Composite 
International 
Diagnostic 
Interview 2.1 
Yes ★ 43% participated at 
the 2-year  
follow-up 
Good 
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Note. Good quality: 3 or 4 stars (★) in selection domain AND 1 or 2 stars in comparability domain AND 2 or 3 stars in outcome/exposure domain; Fair 
quality: 2 stars in selection domain AND 1 or 2 stars in comparability domain AND 2 or 3 stars in outcome/exposure domain; Poor quality: 0 or 1 star in 
selection domain OR 0 stars in comparability domain OR 0 or 1 stars in outcome/exposure domain.
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3.3. Study characteristics  
Table 2 presents the qualitative synthesis of the five studies meeting all inclusion criteria. One study 
was conducted in the United Kingdom (McBeth et al., 2007), two studies were conducted in The 
Netherlands (Generaal et al., 2016; Tak et al., 2009), one in Finland (Paananen et al., 2015) and one in 
Sweden (Schell et al., 2008). The included studies were published between 2007 and 2016. 
Most studies used samples which were socioeconomically representative with large sample sizes. 
Sample sizes ranged from 121 to 2039 participants. With respect to gender, four studies presented data 
on a combination of male and female participants, one study reported on male and female participants 
separately. In most studies age ranged from 18 to 75 years (Generaal et al., 2016; McBeth et al., 2007; 
Tak et al., 2009), one study was conducted in young adults at age 22 (Paananen et al., 2015), and in one 
study the participants were on average 43 (males) and 47 (females) years old (Schell et al., 2008).  
The HPA axis functioning was measured through saliva cortisol in three of the studies (Generaal et 
al., 2016; McBeth et al., 2007; Schell et al., 2008), through serum cortisol in one study (Paananen et al., 
2015), and through 24-h urinary free cortisol (UFC) in the last study (Tak et al., 2009).  
Of the five included studies, two studies focused on musculoskeletal pain as the outcome (Generaal 
et al., 2016; Paananen et al., 2015), one study examined musculoskeletal functional somatic symptoms 
(FSS) (Tak et al., 2009), one study focused on chronic widespread pain (Beth et al., 2007), and the last 
study examined pain in the neck, shoulder and back (Schell et al., 2008). 
Four studies used self-reports and the other study used interviews to diagnose CP. All five 
publications reported on community-based samples and free of CP at baseline. Moderation analyses of 
age was executed in one study (Tak et al., 2009) and of gender was executed in two studies (Schell et 
al., 2008, Tak et al., 2009), although these analyses concern cross-sectional data.  
Two studies examined traumatic life events, as adverse life events (Generaal et al., 2016) and 
threatening life events (McBeth et al., 2007), in relation to onset of CP. Only the adverse life events 
were examined as a moderator in the relation between HPA axis functioning and CP. The adverse events 
were categorized in separate events and the ones that strongly correspond to traumatic life events were 
included in the current review. The threatening life events were only indicated with the total number of 
events, with no distinction in separate events in relation to CP. 
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Table 2 
Study characteristics and results. 
 
 
 
 
Study Design Location Follow-Up 
Period 
(years/months) 
Sample 
cohort (N) 
Age at baseline in 
years, mean (M) or 
median (Mdn) 
Cortisol 
computationsa 
Outcome 
 
Statistical 
methods 
Main findings 
Generaal et al. 
(2016) 
Prospective 
cohort study 
The Netherlands 2, 4 and 6 years 2039 females 
and males 
 
 
18-65 
(M = 41.6) 
Mean cortisol 
level of two 
evenings 
Musculoskeletal 
pain 
Proportional 
hazards models 
for repeated 
measures 
A dysfunctional HPA 
axis,  presented as low 
or high evening 
cortisol, was not 
associated with 
new-onset 
musculoskeletal pain 
(HR = 1.09, 95% CI = 
0.97, 1.23) 
McBeth et al. 
(2007) 
Prospective 
cohort study 
United Kingdom 15 months 241 females 
and males 
 
25-65 
(Mdn = 45.1) 
Fixed time 
points of 
evening cortisol 
levels 
categorized in 
high and low 
Chronic 
widespread pain 
Multivariate 
logistic regression 
High evening cortisol 
levels increased the 
risk of new-onset 
chronic widespread 
pain of at-risk adults 
(low: OR = 3.52, CI = 
1.38, 8.97; high: 2.01, 
95% CI = 0.53, 7.59)b 
Paananen et al. 
(2015) 
Prospective 
cohort study 
Finland 4 years 366 females 
and 439 males 
18 
(M = 18.3) 
Mean cortisol 
on a stress test 
with 8 blood 
samples; 
preceding the 
test (0 min.), 
after 
completing (15 
min.), and at 25, 
35, 45, 60, 75 
and 105 
minutes 
Musculoskeletal 
pain 
Multivariate 
logistic regression 
Low cortisol levels in 
young females 
increased the risk  
of musculoskeletal 
pain onset (low: OR = 
1.80, CI = 0.90, 3.70; 
high: 1.10, CI = 0.40, 
2.80), but not for 
males (low: OR = 
0.60, 95% CI = 0.30, 
1.50; high: OR = 0.80, 
CI = 0.30, 1.80b 
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Table 2 (continued) 
Study Design Location Follow-Up 
Period 
(years/months) 
Sample  
cohort (N) 
Age at baseline in  
years, mean (M) or 
median (Mdn) 
Cortisol 
computationsa 
Outcome 
 
Statistical 
methods 
Main findings 
Schell et al. 
(2008) 
Prospective 
cohort study 
Sweden 1 year 53 females and 
68 males 
Females M = 47 and   
males M = 43 
 
Mean cortisol 
level of four 
time points 
during 12h 
(upon 
wakening, 
lunch, dinner 
and bed time) 
Pain (0-10) in 
neck, shoulder, 
upper back and 
low back 
Linear regression 
analyses 
No significant 
association was 
found between 
altered cortisol 
levels and the 
onset of pain 
symptoms* 
 
Tak et al. 
(2009) 
Prospective 
cohort study 
The Netherlands 2 years 388 females 
and 353 males 
28-75 
(M = 53.1) 
Mean cortisol 
concentration of 
two samples on 
consecutive 
days 
Musculoskeletal 
FSS 
Multivariable 
logistic regression 
24-h UFC 
excretion did not 
predict new-
onset 
musculoskeletal 
FSS (OR = 1.11, 
95% CI = 0.89, 
1.39) and 
provide no 
evidence of HPA 
dysfunction and 
the onset of 
musculoskeletal 
FSS 
Note. HPA = hypothalamic-pituitary-adrenal; FSS = functional somatic symptoms; OR = odds ratio; 95% CI = 95% confidence interval.  
aCorresponding cortisol measurements were used for analyses in the current study: mean cortisol levels from morning till evening and mean evening cortisol levels. bThe 
dysfunctional HPA axis was observed as a predictor of new-onset chronic pain. *The associated statistical data was not provided in the study of Schell et al. (2008).
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3.4. Systematic review 
3.4.1. Cortisol levels and chronic pain  
The main findings of the five studies are summarized in Table 2. In a UK cohort, McBeth and 
colleagues (2007) found that high evening cortisol levels in middle-aged psychologically-at-risk adults 
increased the risk of new-onset chronic widespread pain, indicative of HPA axis dysfunction. In a study 
of Finnish young adults, Paananen and colleagues (2015) found that low levels of cortisol at 18 years 
increased the risk of musculoskeletal pain onset at 22 years in females, associated with higher pain 
sensitivity. These two studies presented that both hypocortisolism and hypercortisolism increased the 
risk of the onset of CP. 
Generaal and colleagues (2016) provide evidence that a dysfunctional HPA axis did not lead to 
increased risk of the onset of musculoskeletal pain in Dutch healthy individuals, whether individuals 
had low or high cortisol levels. Nonetheless, individuals who developed CP had higher pain scores at 
baseline and higher evening cortisol levels. In a Swedish healthy working cohort, Schell et al. (2008) 
did not find an association between altered cortisol levels and pain at multiple sites (e.g., neck, shoulder 
and back). However, the reported pain levels at follow-up were substantially low. In a Dutch study, Tak 
and colleagues (2009) found no evidence of altered cortisol levels in healthy individuals that increased 
the risk of new-onset musculoskeletal FSS.  
3.4.2. Influence of age on HPA axis functioning and chronic pain 
Three of the five studies examined the influence of age on CP. In the study of Tak et al. (2009) no 
association emerged with the moderator age in the relation between a dysfunctional HPA axis and 1-
year musculoskeletal FSS, although the analysis was cross-sectional in nature.  
The two following studies examined age in relation to the onset of CP, but the HPA axis function 
was disregarded. The cohort of McBeth et al. (2007) showed that individuals with new-onset chronic 
widespread pain were older than individuals free of pain (median age 51.9 years and 47.6 years, 
respectively). Similarly, the study of Generaal et al. (2016) showed that individuals who developed 
musculoskeletal pain were significantly older.  
3.4.3. Influence of gender on HPA axis functioning and chronic pain 
All five studies reported findings of the influence of gender in the onset of CP, although moderation 
analyses, longitudinal of nature, were not conducted. The study of Paananen and colleagues (2015) 
explicitly concentrated on gender discrepancy by examining females and males separately in the onset 
of CP. The study findings indicated that a greater risk of a dysfunctional HPA axis, presented as 
hypocortisolism, is followed by a higher number of CP in females. The cohort of Generaal et al. (2016) 
presented similar findings, indicating that individuals that developed CP were mostly female. In 
contrast, Schell and colleagues (2008) cross-sectionally found an association between high cortisol and 
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reported pain in males, whereas such association was not found in individuals who remain free of pain. 
Furthermore, the total sum of reported pain at follow-up was higher for females compared to males.  
Tak and colleagues (2009) presented a significant cross-sectional association between females and 
the number of 1-year musculoskeletal FSS (OR = 2.15, 95% CI = 1.46, 3.16). However, in the analysis 
with gender as moderator in the cross-sectional relation between 24-h UFC and 1-year FSS no 
association emerged. The cohort of Beth and colleagues (2007) was the only study that did not present 
differences in new-onset CP in terms of gender (proportion female 67.9% and male 69.0%, 
respectively). 
3.4.4. Influence of traumatic life events on HPA axis functioning and chronic pain 
Two of the five studies reported on traumatic life events. The study of McBeth et al. (2007) found 
that individuals with two or more threatening life events (e.g., illness subject or close relative, death 
first-degree relative, divorce or relation problems) in the six months prior to follow-up, were more likely 
to develop chronic widespread pain (OR = 1.69, 95% CI = 0.68, 4.22*). HPA axis functioning was 
disregarded in the association between threatening life events and CP. In the cohort of Generaal et al. 
(2016), positive associations were found between adverse life events and the onset of musculoskeletal 
pain over six years. The associations were significant for divorce (HR = 1.49, 95% CI = 1.02, 2.18, p = 
0.040), primarily death of others than friend or family, relationships problems and physical or sexual 
abuse (HR = 1.59, 95% CI = 1.18, 2.14, p = 0.003). The analysis with adverse life events as moderator 
in the relation between HPA axis functioning (evening cortisol) and new-onset musculoskeletal pain 
showed a statistical trend close to significance (p = 0.06**). In addition, the number of individuals who 
developed CP reported higher levels of adverse events at baseline. 
 
*The odds ratio in the study of McBeth et al. (2007) was provided without p-value. 
**The p-value in the study of Generaal et al. (2016) was provided with two decimals. 
 
3.5. Meta-analysis  
Suitable data from three of the five studies were pooled for the meta-analysis. Two other studies 
used hazard ratio and linear regression which produced estimates of association that could not be 
included in the meta-analysis. The three included studies covered 1787 participants. Estimated OR of 
one study was stratified by gender, while the other two studies reported combined ORs, together 
producing a total of four estimates. 
Figure 3 presents a forest plot with effect sizes and 95% CIs. The primary meta-analysis of the three 
studies found that the dysfunctional HPA axis slightly increased, although not significant, the risk on 
onset of CP (OR = 1.15, 95% CI = 0.83, 1.59; I2 = 18.35%, p = 0.299) in a random-effects model. The 
I2 statistic shows that the estimates are consistent across the three studies. The studies of Generaal et al. 
(2016) and Schell et al. (2008), that could not be included in the meta-analysis, did not present evidence 
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that a dysfunctional HPA axis increased the risk for the onset of CP. These findings are broadly 
consistent with the results of the meta-analysis.  
Two of the three studies provided statistical data on the differences between high or low cortisol 
levels in relation to onset of CP which could be used for analysis. Differences in cortisol levels provided 
a non-significant finding (Q (1) = 0.24 (1), p = 0.626) in the relationship between the dysfunctional 
HPA axis and onset of CP. The subgroups with high and low cortisol levels separately did also not show 
a significant causal relation between a dysfunctional HPA axis and onset of CP (high: Z = 0.29, p = 
0.773; and low: Z = 1.05, p = 0.293). Thus, these analyses show that the dysfunctional HPA axis, either 
presented as hypocortisolism or hypercortisolism, was not found as risk factor in the onset of CP. 
However, the risk of onset CP was slightly higher for participants with hypocortisolism in comparison 
to participants with hypercortisolism, although not significant. The forest plot of the subgroup analysis 
of the cortisol levels is shown in Appendix C, Figure C1. 
The limited number of studies has led to adjusted subgroup analyses; therefore, moderation analysis 
of traumatic life events and meta-regression of age were not conducted. The subgroup analysis of gender 
showed a trend towards significance in heterogeneity between males and females (Q (1) = 3.59, p = 
0.058). The higher odds for females with a dysfunctional HPA axis in the onset of CP, in comparison 
to males, seems indicative for the result. The forest plot of the subgroup analysis of gender is shown in 
Appendix C, Figure C2. 
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Figure 3. Meta-analysis forest plot of the studies. 
 
 
 
 
 
 
Author Cortisol Level Outcome Statistics for each study Odds ratio and 95% CI
Odds Lower Upper Relative Relative 
ratio limit limit Z-Value p-Value weight weight
McBeth, 2007 Mixed Combined CWS 2.66 0.84 8.40 1.67 0.10 7.33
Panaanen, 2015 Females Combined MP 1.41 0.60 3.29 0.79 0.43 12.63
Panaanen, 2015 Males Combined MP 0.69 0.30 1.62 -0.84 0.40 12.60
Tak, 2009 Mixed Normal M-FSS 1.11 0.89 1.38 0.92 0.36 67.44
1.15 0.83 1.59 0.84 0.40
0.1 0.2 0.5 1 2 5 10
NOTE: Weights are from random effects analysis
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4. Discussion 
The purpose of the current study was to determine whether a dysfunctional HPA axis can be 
established as a risk factor for the onset of CP, and subsequently whether this presented specifically as 
hypocortisolism. Furthermore, it was investigated whether the factors gender, age and traumatic life 
events, interacted in the relation between HPA axis dysfunction and onset of CP.  
The systematic review shows that young female adults (Paananen et al., 2015) and middle-aged 
psychologically-at-risk adults (Beth et al., 2007), seem more vulnerable to alterations of the HPA axis, 
respectively hypocortisolism and hypercortisolism. These alterations can increase stress, making these 
subpopulations more prone to develop CP. Literature shows that the period of young adulthood comes 
with a biological vulnerability to stress, which could stimulate HPA axis alterations and increase pain 
sensitivity (Walker et al., 2010). The increased risk of the onset of CP in psychologically-at-risk 
individuals could be explained by higher stress leading to HPA axis dysfunction. The subsequent 
alterations in the HPA axis provoke susceptibility to the development of physical symptoms (McBeth 
et al., 2007). In contrast, the other three studies did not provide evidence for a dysfunctional HPA axis 
in relation to the onset of CP in healthy middle-aged individuals (Generaal et al., 2016; Schell et al., 
2008; Tak et al., 2009). Similarly, no strong meta-analytic support was found that the dysfunctional 
HPA axis was indicative of an increased risk in the onset of CP, whether presented as hypocortisolism 
or hypercortisolism. Taking these findings into account, the results are inconclusive, and due to the 
small number of available studies it was not possible to confirm the hypothesized dysfunctional HPA 
axis as a risk factor for the onset of CP.  
Exploring the moderators from the systematic review, gender, age and traumatic life events could 
not be defined as significant moderators in the causal relationship between the dysfunctional HPA axis 
(presented as hypocortisolism) and the onset of CP. Therefore, no support for the hypotheses concerning 
these moderators was found, partially due to insufficient data. However, the systematic review did 
present other associations concerning the moderator variables that are worthwhile to address.  
Cross-sectional findings confirmed that more females developed CP in comparison to males 
(Generaal et al., 2016; Paananen et al., 2015; Tak et al., 2009), which is consistent with previous 
research (Gureje et al., 1998; Hardt et al., 2008; McBeth & Jones, 2007). Similarly, the meta-analysis 
provided a strong, although not significant, trend towards a higher risk for females to develop CP. 
Hormonal factors could play a role in the differences between males and females, as estradiol has been 
shown to activate HPA axis stimulation and to amplify pain perception in females (Kirschbaum et al., 
1996; Rezaii, Hirschberg, Carlström, & Ernberg, 2012). Based on findings of gender discrepancy, it is 
thought that females are more vulnerable to higher stress, experience more stress and report more 
physical symptoms (Kudielka & Kirschbaum, 2005). The alterations in the HPA axis may explain 
hypocortisolism, and the subsequently higher rate of CP in females in the study of Paananen et al. 
(2015). 
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With respect to age, particularly older individuals were more at risk to new-onset CP (Beth et al., 
2007; Generaal et al., 2016), which is in line with previous research, showing a higher chance of onset 
of CP for individuals aged 50 years or older (Gatchel et al., 2007). The altered HPA axis in older 
individuals responds slower to stress, and therefore the stressor lasts longer, making this subpopulation 
more susceptible to new-onset CP (Veldhuis et al., 2013; Wilkinson et al., 1997; Wilkinson et al., 2001). 
Regarding traumatic life events, a nearly significant trend was found in the interaction of traumatic 
life events in the relationship between the HPA axis functioning and new-onset CP. Experiencing a 
traumatic life event was also found as an independent predictor of new-onset CP. These findings are 
consistent with the results of previous research, stating that traumatized individuals show an altered 
HPA axis which contributed to a higher vulnerability to onset of CP (Heim et al., 2000; McEwen & 
Gianaros, 2011; Weissbecker et al., 2006). To illustrate, the vulnerability to CP seems to play a role 
when individuals experience severe stress (McBeth & Jones, 2007). These findings suggest that the 
influence of stressful experiences is inseparable linked to HPA axis dysfunction, and subsequently onset 
of CP.  
In the current study, prospective cohort studies with high methodological quality were included to 
establish that a dysfunctional HPA axis preceded the onset of CP, in order to exclude a reversed 
causality of the association. The systematic review and meta-analysis did not confirm whether HPA 
axis dysfunction occurred prior to the onset of CP. However, previous clinical studies of HPA axis 
dysfunction among clinical patients showed several abnormalities of HPA axis function, with regard to 
hypocortisolism (Griep, Boersma, Lentjes, & Prins, 1998; Gur et al., 2004; Heim et al., 1998; Heim et 
al., 2000; McEwen, 1998; Tak et al., 2011).  
Based on the current findings, it seems plausible that explanations, other than hypothesized, are 
hidden in the association between the dysfunctional HPA axis and CP. It is therefore suggested that 
alterations in the HPA axis is a consequence of CP, rather than demonstrating a risk factor for the onset 
of CP, which agrees with the conclusion of Adler & Geenen (2005). Hereby suggesting that a reversed 
cause and effect seems at play. Another explanation is that CP, together with associated symptoms, 
such as sleep disturbances, depressed mood and lower physical activity, are the cause of alterations in 
the HPA axis (Generaal et al., 2016; McBeth et al., 2007). The latter could account for the dysfunctional 
HPA axis in CP patients and not in individuals that are generally healthy who are not yet experiencing 
CP (Adler & Geenen, 2005). Finally, it is suggested that the variabilities in HPA axis are strongly 
provoked by high psychological stress and therefore increase the vulnerability to onset of CP (Crofford, 
1998). 
The current study has a number of limitations that should be taken into account. First of all, CP is 
a broad, complex concept, either explained by biological or psychological malfunctions (Lumley et al., 
2011; Melzack & Katz, 2013). One can argue that a broader range of multiple physical conditions fall 
under CP, such as chronic fatigue syndrome or irritable bowel syndrome. In the current study these 
conditions were excluded since the hallmark features are different (e.g., fatigue, cramping). 
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Furthermore, one of the selected studies investigated chronic widespread pain alternatively to new-
onset musculoskeletal pain. Musculoskeletal pain is considered to be an important sign of chronic 
widespread pain. Moreover, chronic widespread pain is a fundamental feature of fibromyalgia which 
entails the musculoskeletal system (Butler, Landmark, Glette, Borchgrevink, & Woodhouse, 2016; 
Mourão, Blyth, & Branco, 2010). Physical conditions that affect the musculoskeletal system might be 
considered as overlapping conditions. 
The strict study selection resulted in a low number of included studies, which could compromise 
the true effect, although it also led to a high correspondence between the studies, increasing the 
generalizability and accuracy of the current study. Nonetheless, the number of prospective studies 
researching the causal relation between a dysfunctional HPA axis and the onset of a physical condition 
yielded limited results. 
Another limitation concerns the fact that included prospective cohort studies come from high-
income countries, with high numbers of people that are affected by CP (Muthunarayanan et al., 2015). 
The association between the HPA axis function and the onset of CP could be different in low income 
countries, with limited financial resources to receive adequate healthcare and perhaps with other forms 
of stress (National Center for Health Statistics, 2013).  
Finally, different methods for cortisol measurements were used in the included studies. It is thought 
that studies with corresponding cortisol extraction conditions could provide higher reliability when 
comparing the results. To increase the reliability of the various cortisol measurements, the current study 
attempted to select the cortisol tests that were approximately equal, such as, similar timing of the cortisol 
extraction and exclusive cortisol testing, that is, not in combination with other tests (e.g., cold pressor 
task, dexamethasone suppression test).  
The included studies also presented limitations themselves that must be taken into consideration. 
First, the participants of the included studies were drawn from generally healthy populations. It seems 
important to select certain subgroups with increased sensitivity to onset of CP, such as HPA axis or 
psychological vulnerabilities. Therefore, it would be necessary to further specify and detect certain risk 
groups.  
Furthermore, in most studies the CP outcomes were assessed with self-reports or a computerized 
test. Despite the fact that self-assessment is an effortless and cost-effective method to collect data, it 
can be subject to social desirability bias or misinterpretation of the content of the test, therefore reducing 
the reliability. In addition, self-assessments are in most instances entirely subjective. To improve the 
direction of outcome, it is recommended that a medical professional confirms or refutes the presence of 
CP. Because CP can be approached in multiple ways, it is especially important that the method of 
assessment is consistent and reliable.  
Finally, it is questioned whether the methods to measure cortisol in the selected studies are 
considered reliable. Even though, saliva, serum and urine are assessed as well-stablished methods to 
reflect overall daily cortisol production and to be used as a proxy for HPA axis (dys)functioning, a gold 
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standard for cortisol measurements is not yet available and therefore an adequate assessment of cortisol 
is hard to validate (Hellhammer, Wüst, & Kudielka, 2009; Kushnir, Rockwood, Nelson, Terry, & 
Meikle, 2003; Stalder & Kirschbaum, 2012). Previous publications suggest that hair cortisol collection 
is a more stable and feasible measure of chronic stress. A sample of scalp hair can reflect the past three 
months of cortisol production, whereas more conventional collection is limited by sensitivity to diurnal 
changes, acute stress and nutrition (Gow, Thomson, Rieder, Van Uum, & Koren, 2010; Russell, Koren, 
Rieder, & Van Uum, 2012; Stalder & Kirschbaum, 2012). 
The current study highlights the need for further research to clarify the role of the dysfunctional 
HPA axis, whether as risk factor or contributing factor, in the onset of CP. More prospective cohort 
studies are required to further elucidate the nature of the relationship between the dysfunctional HPA 
axis, whether presented as hypocortisolism or hypercortisolism, and the onset CP. It is recommended 
to get more insight into risk groups, such as investigations into several age ranges (e.g., young and older 
adults), gender discrepancy and individuals with psychological vulnerabilities in relation to the 
dysfunctional HPA axis and new-onset CP. 
The current findings seem to lead to a cascade of causes and effects, therefore suggesting further 
exploration to quantify the impact of traumatic life events and stress as these seem likely to increase the 
sensitivity to CP, leading to altered HPA axis functioning. It is suggested that reducing stress and 
recovering from a psychological trauma could decrease the vulnerability to HPA axis dysfunction and 
that this may be essential for both prevention and treatment of CP (Weissbecker et al., 2006) 
Furthermore, the extent of experienced pain must be considered in further research, which seems to 
influence whether the HPA axis shows alterations. These suggestions are recommended directions for 
further research but require further hypothesis-driven scrutinization.  
In conclusion, the main finding points out that the dysfunctional HPA axis is not confirmed as a 
risk factor for the onset of CP. The relationship between the dysfunctional HPA axis and CP is 
complicated and many of the investigated mechanisms are likely to be involved. HPA axis alterations 
exclusively become apparent once the pain is severe. Individuals experiencing severe stress, caused for 
instance by traumatic life events, influences the transition from pain to CP, subsequently leading to 
HPA axis dysfunction. Furthermore, the HPA axis seems altered through old age and gender (female) 
which increases the risk to onset of CP. Future findings could offer new perspectives to individuals that 
do not yet experience CP and make contributions to prevent the transition to CP by focusing on stress 
as important moderating factor leading to HPA axis alterations. 
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Appendix A 
 
Search String: predictors of Medically Unexplained Physical Symptoms 
 
PUBMED  
((("Risk Factors"[majr] OR "risk factor"[ti] OR "risk factors"[ti] OR "Risk Assessment"[majr] OR "risk 
assessment"[ti] OR "Risk stratification"[ti] OR "prediction model"[ti] OR "prediction models"[ti] OR 
"predictive"[ti] OR "predicts"[ti] OR "predictor"[ti] OR "predictors"[ti] OR "predicted"[ti] OR 
"prediction"[ti]) AND ("Medically Unexplained Symptoms"[majr] OR "medically unexplained 
symptom"[ti] OR "medically unexplained symptoms"[ti] OR "medically unexplained physical 
symptom"[ti] OR "medically unexplained physical symptoms"[ti] OR "Medically Unexplained 
Syndrome"[ti] OR "bodily distress syndrome"[ti] OR "wide spread pain"[ti] OR "widespread pain"[ti] 
OR "widespread pain"[ti] OR "widespread body pain"[ti] OR "musculoskeletal pain"[ti] OR "multisite 
pain"[ti] OR "functional somatic syndrome"[ti] OR "functional somatic syndromes"[ti] OR "functional 
syndrome"[ti] OR "functional somatic symptom"[ti] OR "functional somatic symptoms"[ti] OR 
"functional disorders"[ti] OR "central sensitivity syndrome"[ti] OR "central sensitivity syndromes"[ti] 
OR "central sensitization"[ti] OR "Central Nervous System Sensitization"[majr] OR "somatisation" OR 
"central sensitisation"[ti] OR "Myofascial Pain Syndromes"[majr] OR "myofascial pain syndrome"[ti] 
OR "chronic vulvar pain"[ti] OR "Vulvodynia"[majr] OR "vulvodynia"[ti] OR "Tension-type 
Headache"[majr] OR "tension-type headache"[ti] OR "tension headache"[ti] OR "stress headache"[ti] 
OR "idiopathic headache"[ti] OR "psychogenic headache"[ti] OR "Fibromyalgia"[majr] OR 
"fibromyalgia"[ti] OR "Fatigue Syndrome, Chronic"[majr] OR "chronic fatigue syndrome"[ti] OR 
"myalgic encephalomyelitis"[ti] OR "Irritable Bowel Syndrome"[majr] OR "irritable bowel 
syndrome"[ti] OR "Cystitis, Interstitial"[majr] OR "interstitial cystitis"[ti] OR "Restless Legs 
Syndrome"[majr] OR "restless legs syndrome"[ti] OR "restless-legs syndromes"[ti] OR "restless legs 
syndrome"[ti] OR "restless-legs syndromes"[ti] OR "psychosomatic pain"[ti] OR "psychosomatic 
syndrome"[ti] OR "psychosomatic syndromes"[ti] OR "Somatoform Disorders"[majr] OR "somatoform 
disorder"[ti] OR "somatoform disorders"[ti] OR "somatoform pain disorder"[ti] OR "somatoform pain 
disorders"[ti] OR "somatization"[ti] OR "somatisation"[ti] OR "Back Pain"[majr] OR "back pain"[ti] 
OR "bladder pain syndrome"[ti] OR "Tinnitus"[majr] OR "tinnitus"[ti] OR "Vertigo"[majr] OR 
"vertigo"[ti] OR "vertigos"[ti] OR "Chronic primary pain"[ti] OR "complex regional pain syndrome 
1"[ti] OR "complex regional pain syndrome i"[ti] OR "complex regional pain syndrome type 1"[ti] OR 
"complex regional pain syndrome type i"[ti] OR "pain disorder"[ti] OR "pain disorders"[ti] OR 
"Whiplash Injuries"[majr] OR "whiplash"[ti] OR "chronic pelvic pain"[ti] OR "chronic neck pain"[ti] 
OR "nonspecific chest pain"[ti] OR "non-specific chest pain"[ti] OR "non-cardiac chest pain"[ti] OR 
"chronic complainer"[ti] OR "Neurasthenia"[ti] OR "Neurasthenia"[majr] OR "psychophysiological 
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disorder"[ti] OR "psychophysiological disorders"[ti] OR "psychophysiologic disorders"[majr])) OR 
(("Case-control Studies"[mesh] OR "case control study"[tw] OR "control study"[tw] OR "Cohort 
Studies"[Mesh] OR "cohort study"[tw] OR "Follow-Up Studies"[mesh] OR "Longitudinal 
Studies"[mesh] OR "Prospective Studies"[mesh] OR "Retrospective Studies"[mesh] OR "Follow-Up 
Study"[tw] OR "Longitudinal Study"[tw] OR "Prospective Study"[tw] OR "Retrospective Study"[tw]) 
AND ("Risk Factors"[mesh] OR "risk factor"[tw] OR "risk factors"[tw] OR "Risk Assessment"[mesh] 
OR "risk assessment"[tw] OR "Risk stratification"[tw] OR "prediction model"[tw] OR "prediction 
models"[tw] OR "predictive"[tw] OR "predicts"[tw] OR "predictor"[tw] OR "predictors"[tw] OR 
"predicted"[tw] OR "prediction"[tw]) AND ("Medically Unexplained Symptoms"[majr] OR "medically 
unexplained symptom"[ti] OR "medically unexplained symptoms"[ti] OR "medically unexplained 
physical symptom"[ti] OR "medically unexplained physical symptoms"[ti] OR "Medically 
Unexplained Syndrome"[ti] OR "bodily distress syndrome"[ti] OR "wide spread pain"[ti] OR 
"widespread pain"[ti] OR "widespread pain"[ti] OR "widespread body pain"[ti] OR "musculoskeletal 
pain"[ti] OR "multisite pain"[ti] OR "functional somatic syndrome"[ti] OR "functional somatic 
syndromes"[ti] OR "functional syndrome"[ti] OR "functional somatic symptom"[ti] OR "functional 
somatic symptoms"[ti] OR "functional disorders"[ti] OR "central sensitivity syndrome"[ti] OR "central 
sensitivity syndromes"[ti] OR "central sensitization"[ti] OR "Central Nervous System 
Sensitization"[majr] OR "somatisation" OR "central sensitisation"[ti] OR "Myofascial Pain 
Syndromes"[majr] OR "myofascial pain syndrome"[ti] OR "chronic vulvar pain"[ti] OR 
"Vulvodynia"[majr] OR "vulvodynia"[ti] OR "Tension-type Headache"[majr] OR "tension-type 
headache"[ti] OR "tension headache"[ti] OR "stress headache"[ti] OR "idiopathic headache"[ti] OR 
"psychogenic headache"[ti] OR "Fibromyalgia"[majr] OR "fibromyalgia"[ti] OR "Fatigue Syndrome, 
Chronic"[majr] OR "chronic fatigue syndrome"[ti] OR "myalgic encephalomyelitis"[ti] OR "Irritable 
Bowel Syndrome"[majr] OR "irritable bowel syndrome"[ti] OR "Cystitis, Interstitial"[majr] OR 
"interstitial cystitis"[ti] OR "Restless Legs Syndrome"[majr] OR "restless legs syndrome"[ti] OR 
"restless-legs syndromes"[ti] OR "restless legs syndrome"[ti] OR "restless-legs syndromes"[ti] OR 
"psychosomatic pain"[ti] OR "psychosomatic syndrome"[ti] OR "psychosomatic syndromes"[ti] OR 
"Somatoform Disorders"[majr] OR "somatoform disorder"[ti] OR "somatoform disorders"[ti] OR 
"somatoform pain disorder"[ti] OR "somatoform pain disorders"[ti] OR "somatization"[ti] OR 
"somatisation"[ti] OR "Back Pain"[majr] OR "back pain"[ti] OR "bladder pain syndrome"[ti] OR 
"Tinnitus"[majr] OR "tinnitus"[ti] OR "Vertigo"[majr] OR "vertigo"[ti] OR "vertigos"[ti] OR "Chronic 
primary pain"[ti] OR "complex regional pain syndrome 1"[ti] OR "complex regional pain syndrome 
i"[ti] OR "complex regional pain syndrome type 1"[ti] OR "complex regional pain syndrome type i"[ti] 
OR "pain disorder"[ti] OR "pain disorders"[ti] OR "Whiplash Injuries"[majr] OR "whiplash"[ti] OR 
"chronic pelvic pain"[ti] OR "chronic neck pain"[ti] OR "nonspecific chest pain"[ti] OR "non-specific 
chest pain"[ti] OR "non-cardiac chest pain"[ti] OR "chronic complainer"[ti] OR "Neurasthenia"[ti] OR 
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"Neurasthenia"[majr] OR "psychophysiological disorder"[ti] OR "psychophysiological disorders"[ti] 
OR "psychophysiologic disorders"[majr]))) AND (english[la] OR dutch[la])  
 
Web of Science  
((TI=("Risk Factors" OR "risk factor" OR "risk factors" OR "Risk Assessment" OR "risk assessment" 
OR "Risk stratification" OR "prediction model" OR "prediction models" OR "predictive" OR "predicts" 
OR "predictor" OR "predictors" OR "predicted" OR "prediction") AND TI=("Medically Unexplained 
Symptoms" OR "medically unexplained symptom" OR "medically unexplained symptoms" OR 
"medically unexplained physical symptom" OR "medically unexplained physical symptoms" OR 
"Medically Unexplained Syndrome" OR "Medically Unexplained Syndrome" OR "bodily distress 
syndrome" OR "wide spread pain" OR "widespread pain" OR "widespread pain" OR "widespread body 
pain" OR "musculoskeletal pain" OR "multisite pain" OR "functional somatic syndrome" OR 
"functional somatic syndromes" OR "functional syndrome" OR "functional somatic symptom" OR 
"functional somatic symptoms" OR "functional disorders" OR "central sensitivity syndrome" OR 
"central sensitivity syndromes" OR "central sensitization" OR "Central Nervous System Sensitization" 
OR "somatisation" OR "central sensitisation" OR "Myofascial Pain Syndromes" OR "myofascial pain 
syndrome" OR "chronic vulvar pain" OR "Vulvodynia" OR "tension-type headache" OR "tension 
headache" OR "stress headache" OR "idiopathic headache" OR "psychogenic headache" OR 
"fibromyalgia" OR "Fatigue Syndrome, Chronic" OR "chronic fatigue syndrome" OR "myalgic 
encephalomyelitis" OR "irritable bowel syndrome" OR "Cystitis, Interstitial" OR "interstitial cystitis" 
OR “painful bladder syndrome” OR "restless-legs syndromes" OR "restless legs syndrome" OR 
"restless- legs syndromes" OR "psychosomatic pain" OR "psychosomatic syndrome" OR 
"psychosomatic syndromes" OR "somatoform disorder" OR "somatoform disorders" OR "somatoform 
pain disorder" OR "somatoform pain disorders" OR "somatization" OR "somatisation" OR "back pain" 
OR "bladder pain syndrome" OR "Tinnitus" OR "vertigo" OR "vertigos" OR "Chronic primary pain" 
OR "complex regional pain syndrome 1" OR "complex regional pain syndrome i" OR "complex 
regional pain syndrome type 1" OR "complex regional pain syndrome type i" OR "pain disorder" OR 
"pain disorders" OR "whiplash" OR "chronic pelvic pain" OR "chronic neck pain" OR "nonspecific 
chest pain" OR "non-specific chest pain" OR "non-cardiac chest pain" OR "chronic complainer" OR 
"Neurasthenia" OR "psychophysiological disorder" OR "psychophysiological disorders")) OR 
(TS=("case control study" OR "control study" OR "cohort study" OR "Follow-Up Study" OR 
"Longitudinal Study" OR "Prospective Study" OR "Retrospective Study") AND TS=("Risk Factors" 
OR "risk factor" OR "risk factors" OR "Risk Assessment" OR "risk assessment" OR "Risk 
stratification" OR "prediction model" OR "prediction models" OR "prospective study" OR "prospective 
study" OR "predictive" OR "predicts" OR "predictor" OR "predictors" OR "predicted" OR "prediction") 
AND TI=("Medically Unexplained Symptoms" OR "medically unexplained symptom" OR "medically 
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unexplained symptoms" OR "medically unexplained physical symptom" OR "medically unexplained 
physical symptoms" OR "Medically Unexplained Syndrome" OR "Medically Unexplained Syndrome" 
OR "bodily distress syndrome" OR "wide spread pain" OR "widespread pain" OR "widespread pain" 
OR "widespread body pain" OR "musculoskeletal pain" OR "multisite pain" OR "functional somatic 
syndrome" OR "functional somatic syndromes" OR "functional syndrome" OR "functional somatic 
symptom" OR "functional somatic symptoms" OR "functional disorders" OR "central sensitivity 
syndrome" OR "central sensitivity syndromes" OR "central sensitization" OR "Central Nervous System 
Sensitization" OR "somatisation" OR "central sensitisation" OR "Myofascial Pain Syndromes" OR 
"myofascial pain syndrome" OR "chronic vulvar pain" OR "Vulvodynia" OR "tension-type headache" 
OR "tension headache" OR "stress headache" OR "idiopathic headache" OR "psychogenic headache" 
OR "fibromyalgia" OR "Fatigue Syndrome, Chronic" OR "chronic fatigue syndrome" OR "myalgic 
encephalomyelitis" OR "irritable bowel syndrome" OR "Cystitis, Interstitial" OR "interstitial cystitis" 
OR “painful bladder syndrome” OR "restless-legs syndromes" OR "restless legs syndrome" OR 
"restless- legs syndromes" OR "psychosomatic pain" OR "psychosomatic syndrome" OR 
"psychosomatic syndromes" OR "somatoform disorder" OR "somatoform disorders" OR "somatoform 
pain disorder" OR "somatoform pain disorders" OR "somatization" OR "somatisation" OR "back pain" 
OR "bladder pain syndrome" OR "Tinnitus" OR "vertigo" OR "vertigos" OR "Chronic primary pain" 
OR "complex regional pain syndrome 1" OR "complex regional pain syndrome i" OR "complex 
regional pain syndrome type 1" OR "complex regional pain syndrome type i" OR "pain disorder" OR 
"pain disorders" OR "whiplash" OR "chronic pelvic pain" OR "chronic neck pain" OR "nonspecific 
chest pain" OR "non-specific chest pain" OR "non-cardiac chest pain" OR "chronic complainer" OR 
"Neurasthenia" OR "psychophysiological disorder" OR "psychophysiological disorders"))) AND 
la=(english OR dutch)  
 
PsycINFO 
Strategie 1 in losse delen:  
(MJ("Risk Factor" OR "risk factor" OR "risk factors" OR "Risk Assessment" OR "risk assessment" OR 
"Risk stratification" OR "prediction model" OR ("Prediction" AND "Model") OR "prediction models" 
OR "predictive" OR "predicts" OR "predictor" OR "predictors" OR "predicted" OR "prediction") OR 
TI("Risk Factor" OR "risk factor" OR "risk factors" OR "Risk Assessment" OR "risk assessment" OR 
"Risk stratification" OR "prediction model" OR ("Prediction" AND "Model") OR "prediction models" 
OR "predictive" OR "predicts" OR "predictor" OR "predictors" OR "predicted" OR "prediction") OR 
DE("Risk Factor" OR "risk factor" OR "risk factors" OR "Risk Assessment" OR "risk assessment" OR 
"Risk stratification" OR "prediction model" OR ("Prediction" AND "Model") OR "prediction models" 
OR "predictive" OR "predicts" OR "predictor" OR "predictors" OR "predicted" OR "prediction"))  
AND  
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MJ("Mental Disorders due to General Medical Conditions" OR "Medically Unexplained Symptoms" 
OR "medically unexplained symptom" OR "medically unexplained symptoms" OR "medically 
unexplained physical symptom" OR "medically unexplained physical symptoms" OR "Medically 
Unexplained Syndrome" OR "bodily distress syndrome" OR "wide spread pain" OR "widespread pain" 
OR "widespread pain" OR "widespread body pain" OR "musculoskeletal pain" OR "multisite pain" OR 
"functional somatic syndrome" OR "functional somatic syndromes" OR "functional syndrome" OR 
"functional somatic symptom" OR "functional somatic symptoms" OR "functional disorders" OR 
"central sensitivity syndrome" OR "central sensitivity syndromes" OR "central sensitization" OR 
"Central Nervous System Sensitization" OR "somatisation" OR "central sensitisation" OR "Myofascial 
Pain" OR "myofascial pain syndrome" OR "chronic vulvar pain" OR "Vulvodynia" OR "vulvodynia" 
OR "Tension Headache" OR "tension-type headache" OR "tension headache" OR "stress headache" OR 
"idiopathic headache" OR "psychogenic headache" OR "Fibromyalgia" OR "fibromyalgia" OR 
"Chronic Fatigue Syndrome" OR "chronic fatigue syndrome" OR "myalgic encephalomyelitis" OR 
"Irritable Colon" OR "irritable bowel syndrome" OR "Interstitial Cystitis" OR "interstitial cystitis" OR 
"Restless Legs Syndrome" OR "restless legs syndrome" OR "restless-legs syndromes" OR "restless legs 
syndrome" OR "restless-legs syndromes" OR "psychosomatic pain" OR "psychosomatic syndrome" 
OR "psychosomatic syndromes" OR "Somatoform Disorder" OR "somatoform disorder" OR 
"somatoform disorders" OR "somatoform pain disorder" OR "somatoform pain disorders" OR 
"somatization" OR "somatisation" OR "Backache" OR "back pain" OR "bladder pain syndrome" OR 
"Tinnitus" OR "tinnitus" OR "Vertigo" OR "vertigo" OR "vertigos" OR "Chronic primary pain" OR 
"complex regional pain syndrome 1" OR "complex regional pain syndrome i" OR "complex regional 
pain syndrome type 1" OR "complex regional pain syndrome type i" OR "pain disorder" OR "pain 
disorders" OR "Whiplash Injury" OR "whiplash" OR "chronic pelvic pain" OR "chronic neck pain" OR 
"nonspecific chest pain" OR "non-specific chest pain" OR "noncardiac chest pain" OR "non-cardiac 
chest pain" OR "chronic complainer" OR "Neurasthenia" OR "Neurasthenia" OR "psychophysiological 
disorder" OR "psychophysiological disorders" OR "psychosomatic disorder")  
OR  
TI("Medically Unexplained Symptoms" OR "medically unexplained symptom" OR "medically 
unexplained symptoms" OR "medically unexplained physical symptom" OR "medically unexplained 
physical symptoms" OR "Medically Unexplained Syndrome" OR "bodily distress syndrome" OR "wide 
spread pain" OR "widespread pain" OR "widespread pain" OR "widespread body pain" OR 
"musculoskeletal pain" OR "multisite pain" OR "functional somatic syndrome" OR "functional somatic 
syndromes" OR "functional syndrome" OR "functional somatic symptom" OR "functional somatic 
symptoms" OR "functional disorders" OR "central sensitivity syndrome" OR "central sensitivity 
syndromes" OR "central sensitization" OR "Central Nervous System Sensitization" OR "somatisation" 
OR "central sensitisation" OR "Myofascial Pain" OR "myofascial pain syndrome" OR "chronic vulvar 
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pain" OR "Vulvodynia" OR "vulvodynia" OR "Tension Headache" OR "tension-type headache" OR 
"tension headache" OR "stress headache" OR "idiopathic headache" OR "psychogenic headache" OR 
"Fibromyalgia" OR "fibromyalgia" OR "Chronic Fatigue Syndrome" OR "chronic fatigue syndrome" 
OR "myalgic encephalomyelitis" OR "Irritable Colon" OR "irritable bowel syndrome" OR "Interstitial 
Cystitis" OR "interstitial cystitis" OR "Restless Legs Syndrome" OR "restless legs syndrome" OR 
"restless-legs syndromes" OR "restless legs syndrome" OR "restless-legs syndromes" OR 
"psychosomatic pain" OR "psychosomatic syndrome" OR "psychosomatic syndromes" OR 
"Somatoform Disorder" OR "somatoform disorder" OR "somatoform disorders" OR "somatoform pain 
disorder" OR "somatoform pain disorders" OR "somatization" OR "somatisation" OR "Backache" OR 
"back pain" OR "bladder pain syndrome" OR "Tinnitus" OR "tinnitus" OR "Vertigo" OR "vertigo" OR 
"vertigos" OR "Chronic primary pain" OR "complex regional pain syndrome 1" OR "complex regional 
pain syndrome i" OR "complex regional pain syndrome type 1" OR "complex regional pain syndrome 
type i" OR "pain disorder" OR "pain disorders" OR "Whiplash Injury" OR "whiplash" OR "chronic 
pelvic pain" OR "chronic neck pain" OR "nonspecific chest pain" OR "non-specific chest pain" OR 
"noncardiac chest pain" OR "non-cardiac chest pain" OR "chronic complainer" OR "Neurasthenia" OR 
"Neurasthenia" OR "psychophysiological disorder" OR "psychophysiological disorders" OR 
"psychosomatic disorder") DE("Medically Unexplained Symptoms" OR "medically unexplained 
symptom" OR "medically unexplained symptoms" OR "medically unexplained physical symptom" OR 
"medically unexplained physical symptoms" OR "Medically Unexplained Syndrome" OR "bodily 
distress syndrome" OR "wide spread pain" OR "widespread pain" OR "widespread pain" OR 
"widespread body pain" OR "musculoskeletal pain" OR "multisite pain" OR "functional somatic 
syndrome" OR "functional somatic syndromes" OR "functional syndrome" OR "functional somatic 
symptom" OR "functional somatic symptoms" OR "functional disorders" OR "central sensitivity 
syndrome" OR "central sensitivity syndromes" OR "central sensitization" OR "Central Nervous System 
Sensitization" OR "somatisation" OR "central sensitisation" OR "Myofascial Pain" OR "myofascial 
pain syndrome" OR "chronic vulvar pain" OR "Vulvodynia" OR "vulvodynia" OR "Tension Headache" 
OR "tension-type headache" OR "tension headache" OR "stress headache" OR "idiopathic headache" 
OR "psychogenic headache" OR "Fibromyalgia" OR "fibromyalgia" OR "Chronic Fatigue Syndrome" 
OR "chronic fatigue syndrome" OR "myalgic encephalomyelitis" OR "Irritable Colon" OR "irritable 
bowel syndrome" OR "Interstitial Cystitis" OR "interstitial cystitis" OR "Restless Legs Syndrome" OR 
"restless legs syndrome" OR "restless-legs syndromes" OR "restless legs syndrome" OR "restless-legs 
syndromes" OR "psychosomatic pain" OR "psychosomatic syndrome" OR "psychosomatic syndromes" 
OR "Somatoform Disorder" OR "somatoform disorder" OR "somatoform disorders" OR "somatoform 
pain disorder" OR "somatoform pain disorders" OR "somatization" OR "somatisation" OR "Backache" 
OR "back pain" OR "bladder pain syndrome" OR "Tinnitus" OR "tinnitus" OR "Vertigo" OR "vertigo" 
OR "vertigos" OR "Chronic primary pain" OR "complex regional pain syndrome 1" OR "complex 
regional pain syndrome i" OR "complex regional pain syndrome type 1" OR "complex regional pain 
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syndrome type i" OR "pain disorder" OR "pain disorders" OR "Whiplash Injury" OR "whiplash" OR 
"chronic pelvic pain" OR "chronic neck pain" OR "nonspecific chest pain" OR "non-specific chest pain" 
OR "noncardiac chest pain" OR "non-cardiac chest pain" OR "chronic complainer" OR "Neurasthenia" 
OR "Neurasthenia" OR "psychophysiological disorder" OR "psychophysiological disorders" OR 
"psychosomatic disorder"))  
Strategie 2 in losse delen:  
TI("case control study" OR "control study" OR "cohort study" OR "Follow-Up Study" OR 
"Longitudinal Study" OR "Prospective Study" OR "Retrospective Study") OR MJ("case control study" 
OR "control study" OR "cohort study" OR "Follow-Up Study" OR "Longitudinal Study" OR 
"Prospective Study" OR "Retrospective Study") OR DE("case control study" OR "control study" OR 
"cohort study" OR "Follow-Up Study" OR "Longitudinal Study" OR "Prospective Study" OR 
"Retrospective Study")  
AND  
MJ("Mental Disorders due to General Medical Conditions" OR "Medically Unexplained Symptoms" 
OR "medically unexplained symptom" OR "medically unexplained symptoms" OR "medically 
unexplained physical symptom" OR "medically unexplained physical symptoms" OR "Medically 
Unexplained Syndrome" OR "bodily distress syndrome" OR "wide spread pain" OR "widespread pain" 
OR "widespread pain" OR "widespread body pain" OR "musculoskeletal pain" OR "multisite pain" OR 
"functional somatic syndrome" OR "functional somatic syndromes" OR "functional syndrome" OR 
"functional somatic symptom" OR "functional somatic symptoms" OR "functional disorders" OR 
"central sensitivity syndrome" OR "central sensitivity syndromes" OR "central sensitization" OR 
"Central Nervous System Sensitization" OR "somatisation" OR "central sensitisation" OR "Myofascial 
Pain" OR "myofascial pain syndrome" OR "chronic vulvar pain" OR "Vulvodynia" OR "vulvodynia" 
OR "Tension Headache" OR "tension-type headache" OR "tension headache" OR "stress headache" OR 
"idiopathic headache" OR "psychogenic headache" OR "Fibromyalgia" OR "fibromyalgia" OR 
"Chronic Fatigue Syndrome" OR "chronic fatigue syndrome" OR "myalgic encephalomyelitis" OR 
"Irritable Colon" OR "irritable bowel syndrome" OR "Interstitial Cystitis" OR "interstitial cystitis" OR 
"Restless Legs Syndrome" OR "restless legs syndrome" OR "restless-legs syndromes" OR "restless legs 
syndrome" OR "restless-legs syndromes" OR "psychosomatic pain" OR "psychosomatic syndrome" 
OR "psychosomatic syndromes" OR "Somatoform Disorder" OR "somatoform disorder" OR 
"somatoform disorders" OR "somatoform pain disorder" OR "somatoform pain disorders" OR 
"somatization" OR "somatisation" OR "Backache" OR "back pain" OR "bladder pain syndrome" OR 
"Tinnitus" OR "tinnitus" OR "Vertigo" OR "vertigo" OR "vertigos" OR "Chronic primary pain" OR 
"complex regional pain syndrome 1" OR "complex regional pain syndrome i" OR "complex regional 
pain syndrome type 1" OR "complex regional pain syndrome type i" OR "pain disorder" OR "pain 
disorders" OR "Whiplash Injury" OR "whiplash" OR "chronic pelvic pain" OR "chronic neck pain" OR 
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"nonspecific chest pain" OR "non-specific chest pain" OR "noncardiac chest pain" OR "non-cardiac 
chest pain" OR "chronic complainer" OR "Neurasthenia" OR "Neurasthenia" OR "psychophysiological 
disorder" OR "psychophysiological disorders" OR "psychosomatic disorder")  
OR 
TI("Medically Unexplained Symptoms" OR "medically unexplained symptom" OR "medically 
unexplained symptoms" OR "medically unexplained physical symptom" OR "medically unexplained 
physical symptoms" OR "Medically Unexplained Syndrome" OR "bodily distress syndrome" OR "wide 
spread pain" OR "widespread pain" OR "widespread pain" OR "widespread body pain" OR 
"musculoskeletal pain" OR "multisite pain" OR "functional somatic syndrome" OR "functional somatic 
syndromes" OR "functional syndrome" OR "functional somatic symptom" OR "functional somatic 
symptoms" OR "functional disorders" OR "central sensitivity syndrome" OR "central sensitivity 
syndromes" OR "central sensitization" OR "Central Nervous System Sensitization" OR "somatisation" 
OR "central sensitisation" OR "Myofascial Pain" OR "myofascial pain syndrome" OR "chronic vulvar 
pain" OR "Vulvodynia" OR "vulvodynia" OR "Tension Headache" OR "tension-type headache" OR 
"tension headache" OR "stress headache" OR "idiopathic headache" OR "psychogenic headache" OR 
"Fibromyalgia" OR "fibromyalgia" OR "Chronic Fatigue Syndrome" OR "chronic fatigue syndrome" 
OR "myalgic encephalomyelitis" OR "Irritable Colon" OR "irritable bowel syndrome" OR "Interstitial 
Cystitis" OR "interstitial cystitis" OR "Restless Legs Syndrome" OR "restless legs syndrome" OR 
"restless-legs syndromes" OR "restless legs syndrome" OR "restless-legs syndromes" OR 
"psychosomatic pain" OR "psychosomatic syndrome" OR "psychosomatic syndromes" OR 
"Somatoform Disorder" OR "somatoform disorder" OR "somatoform disorders" OR "somatoform pain 
disorder" OR "somatoform pain disorders" OR "somatization" OR "somatisation" OR "Backache" OR 
"back pain" OR "bladder pain syndrome" OR "Tinnitus" OR "tinnitus" OR "Vertigo" OR "vertigo" OR 
"vertigos" OR "Chronic primary pain" OR "complex regional pain syndrome 1" OR "complex regional 
pain syndrome i" OR "complex regional pain syndrome type 1" OR "complex regional pain syndrome 
type i" OR "pain disorder" OR "pain disorders" OR "Whiplash Injury" OR "whiplash" OR "chronic 
pelvic pain" OR "chronic neck pain" OR "nonspecific chest pain" OR "non-specific chest pain" OR 
"noncardiac chest pain" OR "non-cardiac chest pain" OR "chronic complainer" OR "Neurasthenia" OR 
"Neurasthenia" OR "psychophysiological disorder" OR "psychophysiological disorders" OR 
"psychosomatic disorder") Limit to english/dutch  
 
Embase  
(((exp *"Risk Factor"/ OR "risk factor".ti OR "risk factors".ti OR exp *"Risk Assessment"/ OR "risk 
assessment".ti OR "Risk stratification".ti OR "prediction model".ti OR (*"Prediction"/ AND "Model"/) 
OR "prediction models".ti OR "predictive".ti OR "predicts".ti OR "predictor".ti OR "predictors".ti OR 
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"predicted".ti OR "prediction".ti) AND (*"Medically Unexplained Symptoms"/ OR "medically 
unexplained symptom".ti OR "medically unexplained symptoms".ti OR "medically unexplained 
physical symptom".ti OR "medically unexplained physical symptoms".ti OR "Medically Unexplained 
Syndrome".ti OR "bodily distress syndrome".ti OR "wide spread pain".ti OR "widespread pain".ti OR 
"widespread pain".ti OR "widespread body pain".ti OR "musculoskeletal pain".ti OR "multisite pain".ti 
OR "functional somatic syndrome".ti OR "functional somatic syndromes".ti OR "functional 
syndrome".ti OR "functional somatic symptom".ti OR "functional somatic symptoms".ti OR 
"functional disorders".ti OR "central sensitivity syndrome".ti OR "central sensitivity syndromes".ti OR 
"central sensitization".ti OR *"Central Nervous System Sensitization"/ OR "somatisation".ti OR 
"central sensitisation".ti OR *"Myofascial Pain"/ OR "myofascial pain syndrome".ti OR "chronic vulvar 
pain".ti OR *"Vulvodynia"/ OR "vulvodynia".ti OR exp *"Tension Headache"/ OR "tension-type 
headache".ti OR "tension headache".ti OR "stress headache".ti OR "idiopathic headache".ti OR 
"psychogenic headache".ti OR *"Fibromyalgia"/ OR "fibromyalgia".ti OR *"Chronic Fatigue 
Syndrome"/ OR "chronic fatigue syndrome".ti OR "myalgic encephalomyelitis".ti OR *"Irritable 
Colon"/ OR "irritable bowel syndrome".ti OR *"Interstitial Cystitis"/ OR "interstitial cystitis".ti OR 
*"Restless Legs Syndrome"/ OR "restless legs syndrome".ti OR "restless-legs syndromes".ti OR 
"restless legs syndrome".ti OR "restless-legs syndromes".ti OR "psychosomatic pain".ti OR 
"psychosomatic syndrome".ti OR "psychosomatic syndromes".ti OR exp *"Somatoform Disorder"/ OR 
"somatoform disorder".ti OR "somatoform disorders".ti OR "somatoform pain disorder".ti OR 
"somatoform pain disorders".ti OR "somatization".ti OR "somatisation".ti OR exp *"Backache"/ OR 
"back pain".ti OR "bladder pain syndrome".ti OR exp *"Tinnitus"/ OR "tinnitus".ti OR exp *"Vertigo"/ 
OR "vertigo".ti OR "vertigos".ti OR "Chronic primary pain".ti OR "complex regional pain syndrome 
1".ti OR "complex regional pain syndrome i".ti OR "complex regional pain syndrome type 1".ti OR 
"complex regional pain syndrome type i".ti OR "pain disorder".ti OR "pain disorders".ti OR *"Whiplash 
Injury"/ OR "whiplash".ti OR "chronic pelvic pain".ti OR "chronic neck pain".ti OR "nonspecific chest 
pain".ti OR "non-specific chest pain".ti OR *"noncardiac chest pain"/ OR "non-cardiac chest pain".ti 
OR "chronic complainer".ti OR "Neurasthenia".ti OR *"Neurasthenia"/ OR "psychophysiological 
disorder".ti OR "psychophysiological disorders".ti OR *"psychosomatic disorder"/)) OR ((exp "Case 
control Study"/ OR "case control study".mp OR "control study".mp OR "Cohort Analysis"/ OR "cohort 
study".mp OR "Follow Up"/ OR "Longitudinal Study"/ OR "Prospective Study"/ OR "Retrospective 
Study"/ OR "Follow-Up Study".mp OR "Longitudinal Study".mp OR "Prospective Study".mp OR 
"Retrospective Study".mp) AND (exp "Risk Factor"/ OR "risk factor".ti,ab OR "risk factors".ti,ab OR 
exp "Risk Assessment"/ OR "risk assessment".ti,ab OR "Risk stratification".ti,ab OR "prediction 
model".ti,ab OR ("Prediction"/ AND "Model"/) OR "prediction models".ti,ab OR "predictive".ti,ab OR 
"predicts".ti,ab OR "predictor".ti,ab OR "predictors".ti,ab OR "predicted".ti,ab OR "prediction".ti,ab) 
AND (*"Medically Unexplained Symptoms"/ OR "medically unexplained symptom".ti OR "medically 
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unexplained symptoms".ti OR "medically unexplained physical symptom".ti OR "medically 
unexplained physical symptoms".ti OR "Medically Unexplained  
Syndrome".ti OR "bodily distress syndrome".ti OR "wide spread pain".ti OR "widespread pain".ti OR 
"widespread pain".ti OR "widespread body pain".ti OR "musculoskeletal pain".ti OR "multisite pain".ti 
OR "functional somatic syndrome".ti OR "functional somatic syndromes".ti OR "functional 
syndrome".ti OR "functional somatic symptom".ti OR "functional somatic symptoms".ti OR 
"functional disorders".ti OR "central sensitivity syndrome".ti OR "central sensitivity syndromes".ti OR 
"central sensitization".ti OR *"Central Nervous System Sensitization"/ OR "somatisation".ti OR 
"central sensitisation".ti OR *"Myofascial Pain"/ OR "myofascial pain syndrome".ti OR "chronic vulvar 
pain".ti OR *"Vulvodynia"/ OR "vulvodynia".ti OR exp *"Tension Headache"/ OR "tension-type 
headache".ti OR "tension headache".ti OR "stress headache".ti OR "idiopathic headache".ti OR 
"psychogenic headache".ti OR *"Fibromyalgia"/ OR "fibromyalgia".ti OR *"Chronic Fatigue 
Syndrome"/ OR "chronic fatigue syndrome".ti OR "myalgic encephalomyelitis".ti OR *"Irritable 
Colon"/ OR "irritable bowel syndrome".ti OR *"Interstitial Cystitis"/ OR "interstitial cystitis".ti OR 
*"Restless Legs Syndrome"/ OR "restless legs syndrome".ti OR "restless-legs syndromes".ti OR 
"restless legs syndrome".ti OR "restless-legs syndromes".ti OR "psychosomatic pain".ti OR 
"psychosomatic syndrome".ti OR "psychosomatic syndromes".ti OR exp *"Somatoform Disorder"/ OR 
"somatoform disorder".ti OR "somatoform disorders".ti OR "somatoform pain disorder".ti OR 
"somatoform pain disorders".ti OR "somatization".ti OR "somatisation".ti OR exp *"Backache"/ OR 
"back pain".ti OR "bladder pain syndrome".ti OR exp *"Tinnitus"/ OR "tinnitus".ti OR exp *"Vertigo"/ 
OR "vertigo".ti OR "vertigos".ti OR "Chronic primary pain".ti OR "complex regional pain syndrome 
1".ti OR "complex regional pain syndrome i".ti OR "complex regional pain syndrome type 1".ti OR 
"complex regional pain syndrome type i".ti OR "pain disorder".ti OR "pain disorders".ti OR *"Whiplash 
Injury"/ OR "whiplash".ti OR "chronic pelvic pain".ti OR "chronic neck pain".ti OR "nonspecific chest 
pain".ti OR "non-specific chest pain".ti OR *"noncardiac chest pain"/ OR "non-cardiac chest pain".ti 
OR "chronic complainer".ti OR "Neurasthenia".ti OR *"Neurasthenia"/ OR "psychophysiological 
disorder".ti OR "psychophysiological disorders".ti OR *"psychosomatic disorder"/))) AND (english.la 
OR dutch.la) NOT (conference review OR conference abstract).pt  
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Appendix B 
 
Newcastle-Ottawa Quality Assessment Form for Cohort Studies  
 
Note: A study can be given a maximum of one star for each numbered item within the Selection and 
Outcome categories. A maximum of two stars can be given for Comparability. 
 
Selection  
1.  Representativeness of the exposed cohort  
a)  Truly representative (one star)  
b)  Somewhat representative (one star)  
c)  Selected group  
d)  No description of the derivation of the cohort  
2. Selection of the non-exposed cohort  
a)  Drawn from the same community as the exposed cohort (one star)  
b)  Drawn from a different source  
c)  No description of the derivation of the non-exposed cohort  
3. Ascertainment of exposure  
a)  Secure record (e.g., surgical record) (one star)  
b)  Structured interview (one star)  
c)  Written self-report  
d)  No description  
e)  Other  
4. Demonstration that outcome of interest was not present at start of study  
a) Yes (one star)  
b) No  
 
Comparability  
1. Comparability of cohorts on the basis of the design or analysis controlled for confounders  
a)  The study controls for age, sex and marital status (one star)  
b)  Study controls for other factors (list): medication, psychosocial and physical factors  
(one star)  
c)  Cohorts are not comparable on the basis of the design or analysis controlled for confounders  
  
43 
Outcome  
1. Assessment of outcome  
a)  Independent blind assessment (one star)  
b)  Record linkage (one star)  
c)  Self report 
d)  No description 
e)  Other  
 
2. Was follow-up long enough for outcomes to occur  
a) Yes (one star)  
b) No 
Indicate the median duration of follow-up and a brief rationale for the assessment above: 24 months 
 
3. Adequacy of follow-up of cohorts a) Yes (one star)  
a) Complete follow up- all subject accounted for (one star) 
b) Subjects lost to follow up unlikely to introduce bias- number lost less than or equal to    
    20% or description of those lost suggested no different from those followed (one star) 
c) Follow up rate less than 80% and no description of those lost 
d) No statement 
 
Thresholds for converting the Newcastle-Ottawa scales to AHRQ standards (good, fair, and poor):  
 
Good quality: 3 or 4 stars in selection domain AND 1 or 2 stars in comparability domain AND 2 or 3 
stars in outcome/exposure domain  
Fair quality: 2 stars in selection domain AND 1 or 2 stars in comparability domain AND 2 or 3 stars 
in outcome/exposure domain  
Poor quality: 0 or 1 star in selection domain OR 0 stars in comparability domain OR 0 or 1 stars in 
outcome/exposure domain  
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Appendix C 
 
Figure C1. Meta-analysis forest plot of the subgroup analysis of the cortisol levels and onset of chronic pain.  
  
Group by
Comparison
Author Gender Cortisol Level Outcome Statistics for each study Odds ratio and 95% CI
Odds Lower Upper Relative Relative 
ratio limit limit Z-Value p-Value weight weight
High McBeth, 2007 Mixed High CWS 2.01 0.53 7.61 1.03 0.30 25.77
High Panaanen, 2015 Females High MP 1.10 0.42 2.91 0.19 0.85 35.81
High Panaanen, 2015 Males High MP 0.80 0.33 1.96 -0.49 0.63 38.43
High 1.14 0.48 2.71 0.29 0.77
Low McBeth, 2007 Mixed Low CWS 3.52 1.38 8.97 2.64 0.01 29.84
Low Panaanen, 2015 Females Low MP 1.80 0.89 3.65 1.63 0.10 36.57
Low Panaanen, 2015 Males Low MP 0.60 0.27 1.34 -1.24 0.21 33.59
Low 1.52 0.70 3.32 1.05 0.29
Overall 1.34 0.75 2.39 0.98 0.33
0.1 0.2 0.5 1 2 5 10
NOTE: Weights are from random effects analysis
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Appendix C (continued) 
 
Figure C2. Meta-analysis forest plot of the subgroup analysis of both genders and onset chronic pain. 
 
 
Author Cortisol Level Outcome Statistics for each study Odds ratio and 95% CI
Odds Lower Upper Relative Relative 
ratio limit limit Z-Value p-Value weight weight
Panaanen, 2015 Females High MP 1.10 0.42 2.91 0.19 0.85 20.14
Panaanen, 2015 Females Low MP 1.80 0.89 3.65 1.63 0.10 30.90
Panaanen, 2015 Males High MP 0.80 0.33 1.96 -0.49 0.63 22.69
Panaanen, 2015 Males Low MP 0.60 0.27 1.34 -1.24 0.21 26.26
1.02 0.61 1.69 0.06 0.95
0.1 0.2 0.5 1 2 5 10
NOTE: Weights are from random effects analysis
